Suppr超能文献

在多发性骨髓瘤患者中,挽救性二次自体移植可实现持久缓解。

Durable remission with salvage second autotransplants in patients with multiple myeloma.

机构信息

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Cancer. 2012 Jul 15;118(14):3549-55. doi: 10.1002/cncr.26662. Epub 2011 Nov 15.

Abstract

BACKGROUND

High-dose chemotherapy with autologous hematopoietic cell transplant (auto-HCT) has been shown to improve survival in patients with newly diagnosed multiple myeloma. However, the role of salvage auto-HCT for relapsed patients, particularly in the era of novel therapeutics, is not well defined.

METHODS

The authors performed a retrospective analysis of all 44 myeloma patients (24 men, 20 women) who received a second auto-HCT as salvage between January 3, 1992 and November 4, 2008 at The University of Texas MD Anderson Cancer Center.

RESULTS

Median interval between the first and salvage auto-HCT was 30 months (range, 2-78 months). Median age at salvage HCT was 54 years (range, 38-73 years), and median number of salvage treatment regimens was 2 (range, 0-5). Eleven (25%) patients had high-risk chromosomal abnormalities on conventional cytogenetic studies between diagnosis and salvage auto-HCT. Ten patients (23%) experienced grade 3 or higher nonhematologic toxicity after the salvage auto-HCT. One patient died within 100 days, for a treatment-related mortality of 2%. Best responses after salvage chemotherapy + salvage auto-HCT were as follows: complete response (CR) + near CR, 11%; partial response, 79%; overall response rate, 90%. Eighteen (41%) patients received post auto-HCT maintenance therapy. Median follow-up from salvage HCT was 41 months. Kaplan-Meier estimates of median progression-free survival (PFS) and overall survival (OS) from time of salvage auto-HCT were 12.3 and 31.7 months, respectively. Median OS from the time of diagnosis was 75 months. In a fitted Bayesian multivariate model, shorter time to progression after first auto-HCT, greater number of prior therapies, African American race, and immunoglobulin G subtype were significantly associated with worse OS.

CONCLUSIONS

In selected myeloma patients, a second auto-HCT for salvage therapy is well tolerated, with acceptable toxicity. The overall response rate and PFS are comparable to other salvage regimens.

摘要

背景

高剂量化疗联合自体造血细胞移植(auto-HCT)已被证明可提高新诊断多发性骨髓瘤患者的生存率。然而,在新型治疗药物时代,挽救性 auto-HCT 对复发患者的作用尚不确定。

方法

作者对 1992 年 1 月 3 日至 2008 年 11 月 4 日期间在德克萨斯大学 MD 安德森癌症中心接受第二次挽救性 auto-HCT 的 44 例骨髓瘤患者(24 例男性,20 例女性)进行了回顾性分析。

结果

第一次和挽救性 auto-HCT 之间的中位间隔为 30 个月(范围 2-78 个月)。挽救性 HCT 时的中位年龄为 54 岁(范围 38-73 岁),中位挽救性治疗方案数为 2 个(范围 0-5 个)。在诊断和挽救性 auto-HCT 之间的常规细胞遗传学研究中,11 例(25%)患者存在高危染色体异常。10 例(23%)患者在挽救性 auto-HCT 后出现 3 级或更高的非血液学毒性。1 例患者在 100 天内死亡,治疗相关死亡率为 2%。挽救性化疗+挽救性 auto-HCT 后的最佳反应如下:完全缓解(CR)+接近 CR,11%;部分缓解,79%;总缓解率为 90%。18 例(41%)患者接受了 auto-HCT 后维持治疗。从挽救性 HCT 开始的中位随访时间为 41 个月。从挽救性 auto-HCT 开始的中位无进展生存期(PFS)和总生存期(OS)的 Kaplan-Meier 估计值分别为 12.3 个月和 31.7 个月。从诊断开始的中位 OS 为 75 个月。在拟合的贝叶斯多变量模型中,首次 auto-HCT 后进展时间较短、治疗次数较多、非裔美国人种族和免疫球蛋白 G 亚型与较差的 OS 显著相关。

结论

在选择的骨髓瘤患者中,第二次用于挽救治疗的自体 HCT 耐受性良好,毒性可接受。总体反应率和 PFS 与其他挽救方案相当。

相似文献

引用本文的文献

本文引用的文献

2
Peripheral blood stem cell mobilization tactics.外周血造血干细胞动员策略。
Ann Pharmacother. 2010 Jan;44(1):107-16. doi: 10.1345/aph.1M289. Epub 2009 Dec 8.
8
Multiple myeloma.多发性骨髓瘤
Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验